CLAIMS

1. Use of an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for increasing the density of interferon receptors upon treating a disease associated with a reduced density of interferon receptors, wherein the interferon receptors are interferon α (IFNα) and interferon β (IFNβ) receptors, wherein said disease is selected from the group consisting of hepatitis B, herpes, papilloma virus infection, multiple sclerosis and tobacco smoking-induced immunosuppression associated with a degradation of interferon receptors in smokers.

2. The use of claim 1, wherein said increase of the density of interferon receptors overcomes a resistance to therapy with interferon and/or compensates a reduced expression level of interferon receptors in a long-term therapy with interferon.

3. The use of claim 1, wherein glutaryl histamine is to be administered in a solid dosage form, and a duration of the administration is from 5 days to 12 months.

4. The use of any one of claims 1 to 3, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof in the medicament is from 0.1 to 100 mg/kg of human body weight per day when administered one or more times per day.

5. The use of claim 4, wherein the dose of glutaryl histamine or the pharmaceutically acceptable salt thereof

in the medicament is from 0.1 to 30 mg/kg of human body weight per day when administered one or more times per day.

6. The use of claim 5, wherein the dose of glutaryl histamine or the pharmaceutically acceptable salt thereof in the medicament is from 0.3 to 10 mg/kg of human body weight per day when administered one or more times per day.

7. The use of any one of claims 1 to 3, wherein a single dose of glutaryl histamine in the medicament is 100 mg.